<?xml version="1.0" encoding="UTF-8"?><abstracts-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/abstract/dtd" xmlns:ait="http://www.elsevier.com/xml/ani/ait" xmlns:ce="http://www.elsevier.com/xml/ani/common" xmlns:cto="http://www.elsevier.com/xml/cto/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>http://api.elsevier.com/content/abstract/scopus_id/84907914063</prism:url><dc:identifier>SCOPUS_ID:84907914063</dc:identifier><eid>2-s2.0-84907914063</eid><prism:doi>10.1089/jamp.2013.1058</prism:doi><dc:title>Characterization of a reverse-phase perfluorocarbon emulsion for the pulmonary delivery of tobramycin</dc:title><prism:aggregationType>Journal</prism:aggregationType><srctype>j</srctype><citedby-count>0</citedby-count><prism:publicationName>Journal of Aerosol Medicine and Pulmonary Drug Delivery</prism:publicationName><dc:publisher>Mary Ann Liebert Inc.info@liebertpub.com</dc:publisher><source-id>11700154735</source-id><prism:issn>19412703</prism:issn><prism:volume>27</prism:volume><prism:issueIdentifier>5</prism:issueIdentifier><prism:startingPage>392</prism:startingPage><prism:endingPage>399</prism:endingPage><prism:pageRange>392-399</prism:pageRange><prism:coverDate>2014-01-01</prism:coverDate><dc:creator><author auid="53364262200" seq="1"><ce:initials>R.A.</ce:initials><ce:indexed-name>Orizondo R.A.</ce:indexed-name><ce:degrees>Mse</ce:degrees><ce:surname>Orizondo</ce:surname><ce:given-name>Ryan A.</ce:given-name><preferred-name><ce:initials>R.A.</ce:initials><ce:indexed-name>Orizondo R.</ce:indexed-name><ce:surname>Orizondo</ce:surname><ce:given-name>Ryan A.</ce:given-name></preferred-name><author-url>http://api.elsevier.com/content/author/author_id/53364262200</author-url></author></dc:creator><dc:description><abstract original="y" xml:lang="eng"><publishercopyright>© 2014 Mary Ann Liebert, Inc.</publishercopyright><ce:para>Methods: This study examined emulsion aqueous droplet diameter and number density over 24 hr and emulsion and neat PFC viscosity and surface tension. Additionally, Pseudomonas aeruginosa biofilm growth was measured after 2-hr exposure to emulsion with variable aqueous volume percentages (0.25, 1, and 2.5%) and aqueous tobramycin concentrations (C<inf>a</inf>=0.4, 4, and 40 mg/mL). Lastly, the time course of serum and pulmonary tobramycin concentrations was evaluated following APV and conventional aerosolized delivery of tobramycin in rats.</ce:para><ce:para>Background: Aerosolized delivery of antibiotics is hindered by poor penetration within distal and plugged airways. Antibacterial perfluorocarbon ventilation (APV) is a proposed solution in which the lungs are partially or totally filled with perfluorocarbon (PFC) containing emulsified antibiotics. The purpose of this study was to evaluate emulsion stability and rheological, antibacterial, and pharmacokinetic characteristics.</ce:para><ce:para>Results: The initial aqueous droplet diameter averaged 1.9±0.2 μm with little change over time. Initial aqueous droplet number density averaged 3.5±1.7×10<sup>9</sup>droplets/mL with a significant (p&lt;0.01) decrease over time. Emulsion and PFC viscosity were not significantly different, averaging 1.22±0.03×10<sup>-3</sup>Pa·sec. The surface tensions of PFC and emulsion were 15.0±0.1×10<sup>-3</sup>and 14.6±0.6×10<sup>-3</sup>N/m, respectively, and the aqueous interfacial tensions were 46.7±0.3×10<sup>-3</sup>and 26.9±11.0×10<sup>-3</sup>N/m (p&lt;0.01), respectively. Biofilm growth decreased markedly with increasing C<inf>a</inf>and, to a lesser extent, aqueous volume percentage. Tobramycin delivered via APV yielded 2.5 and 10 times larger pulmonary concentrations at 1 and 4 hr post delivery, respectively, and significantly (p&lt;0.05) lower serum concentrations compared with aerosolized delivery.</ce:para><ce:para>Conclusions: The emulsion is bactericidal, retains the rheology necessary for pulmonary delivery, is sufficiently stable for this application, and results in increased pulmonary retention of the antibiotic.</ce:para></abstract></dc:description><link href="http://api.elsevier.com/content/abstract/scopus_id/84907914063" rel="self"/><link href="http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&amp;scp=84907914063&amp;origin=inward" rel="scopus"/><link href="http://api.elsevier.com/content/search/scopus?query=refeid%282-s2.0-84907914063%29" rel="cited-by"/></coredata><authors><author auid="53364262200" seq="1"><ce:initials>R.A.</ce:initials><ce:indexed-name>Orizondo R.A.</ce:indexed-name><ce:degrees>Mse</ce:degrees><ce:surname>Orizondo</ce:surname><ce:given-name>Ryan A.</ce:given-name><preferred-name><ce:initials>R.A.</ce:initials><ce:indexed-name>Orizondo R.</ce:indexed-name><ce:surname>Orizondo</ce:surname><ce:given-name>Ryan A.</ce:given-name></preferred-name><author-url>http://api.elsevier.com/content/author/author_id/53364262200</author-url></author><author auid="56382802700" seq="2"><ce:initials>C.I.</ce:initials><ce:indexed-name>Babcock C.I.</ce:indexed-name><ce:degrees>MD</ce:degrees><ce:surname>Babcock</ce:surname><ce:given-name>Charlene Irvin</ce:given-name><preferred-name><ce:initials>C.I.</ce:initials><ce:indexed-name>Babcock C.</ce:indexed-name><ce:surname>Babcock</ce:surname><ce:given-name>Charlene Irvin</ce:given-name></preferred-name><author-url>http://api.elsevier.com/content/author/author_id/56382802700</author-url></author><author auid="6505672385" seq="3"><ce:initials>M.L.</ce:initials><ce:indexed-name>Fabiilli M.L.</ce:indexed-name><ce:degrees>PhD</ce:degrees><ce:surname>Fabiilli</ce:surname><ce:given-name>Mario L.</ce:given-name><preferred-name><ce:initials>M.L.</ce:initials><ce:indexed-name>Fabiilli M.</ce:indexed-name><ce:surname>Fabiilli</ce:surname><ce:given-name>Mario L.</ce:given-name></preferred-name><author-url>http://api.elsevier.com/content/author/author_id/6505672385</author-url></author><author auid="55510513600" seq="4"><ce:initials>L.</ce:initials><ce:indexed-name>Pavlovsky L.</ce:indexed-name><ce:degrees>MSE</ce:degrees><ce:surname>Pavlovsky</ce:surname><ce:given-name>Leonid</ce:given-name><preferred-name><ce:initials>L.</ce:initials><ce:indexed-name>Pavlovsky L.</ce:indexed-name><ce:surname>Pavlovsky</ce:surname><ce:given-name>Leonid</ce:given-name></preferred-name><author-url>http://api.elsevier.com/content/author/author_id/55510513600</author-url></author><author auid="7006645138" seq="5"><ce:initials>J.B.</ce:initials><ce:indexed-name>Fowlkes J.B.</ce:indexed-name><ce:degrees>PhD</ce:degrees><ce:surname>Fowlkes</ce:surname><ce:given-name>J. Brian</ce:given-name><preferred-name><ce:initials>J.B.</ce:initials><ce:indexed-name>Fowlkes J.</ce:indexed-name><ce:surname>Fowlkes</ce:surname><ce:given-name>J. Brian</ce:given-name></preferred-name><author-url>http://api.elsevier.com/content/author/author_id/7006645138</author-url></author><author auid="7004534878" seq="6"><ce:initials>J.G.</ce:initials><ce:indexed-name>Younger J.G.</ce:indexed-name><ce:degrees>MD</ce:degrees><ce:surname>Younger</ce:surname><ce:given-name>John G.</ce:given-name><preferred-name><ce:initials>J.G.</ce:initials><ce:indexed-name>Younger J.</ce:indexed-name><ce:surname>Younger</ce:surname><ce:given-name>John G.</ce:given-name></preferred-name><author-url>http://api.elsevier.com/content/author/author_id/7004534878</author-url></author><author auid="7202583317" seq="7"><ce:initials>K.E.</ce:initials><ce:indexed-name>Cook K.E.</ce:indexed-name><ce:degrees>PhD</ce:degrees><ce:surname>Cook</ce:surname><ce:given-name>Keith E.</ce:given-name><preferred-name><ce:initials>K.E.</ce:initials><ce:indexed-name>Cook K.</ce:indexed-name><ce:surname>Cook</ce:surname><ce:given-name>Keith E.</ce:given-name></preferred-name><author-url>http://api.elsevier.com/content/author/author_id/7202583317</author-url></author></authors></abstracts-retrieval-response>
